LivaNova (NASDAQ:LIVN) Downgraded by Wolfe Research to Peer Perform

Wolfe Research downgraded shares of LivaNova (NASDAQ:LIVN) from an outperform rating to a peer perform rating in a research report report published on Wednesday, Marketbeat.com reports.

Several other analysts also recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 target price on shares of LivaNova in a report on Tuesday, January 28th. StockNews.com raised LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 14th. Mizuho lowered their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Finally, Robert W. Baird lifted their price objective on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $64.20.

LivaNova Trading Down 0.6 %

Shares of LivaNova stock opened at $41.45 on Wednesday. LivaNova has a fifty-two week low of $40.37 and a fifty-two week high of $64.47. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of 98.69 and a beta of 1.00. The stock has a 50 day moving average of $47.65 and a 200 day moving average of $49.56.

Insider Transactions at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now owns 7,522 shares in the company, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. State of Alaska Department of Revenue grew its position in LivaNova by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after buying an additional 425 shares during the period. abrdn plc raised its holdings in LivaNova by 43.8% during the third quarter. abrdn plc now owns 232,025 shares of the company’s stock worth $12,191,000 after purchasing an additional 70,618 shares during the last quarter. Emerald Advisers LLC boosted its position in LivaNova by 2.1% during the third quarter. Emerald Advisers LLC now owns 695,505 shares of the company’s stock worth $36,542,000 after purchasing an additional 14,302 shares in the last quarter. Atria Investments Inc raised its stake in shares of LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after buying an additional 331 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D boosted its position in shares of LivaNova by 38.3% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 42,539 shares of the company’s stock worth $2,235,000 after buying an additional 11,782 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.